ADMA (ADMA) CEO uses 85,951 shares to cover RSU tax obligations

Rhea-AI Filing Summary

ADMA Biologics President and CEO Adam S. Grossman reported tax-related share withholdings rather than market trades. On March 6–7, 2026, a total of 85,951 shares of Common Stock were withheld at $15.39 per share to satisfy mandatory tax obligations upon vesting of restricted stock units, as noted in the footnotes. After these withholdings, he directly held 2,118,777 shares of Common Stock. Separate holding entries show additional indirect ownership of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC, entities over which he has control roles.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Grossman Adam S

Role President and CEO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	29,513	$15.39	$454K
Tax Withholding	Common Stock	56,438	$15.39	$869K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,118,777 shares (Direct); Common Stock — 1,143,426 shares (Indirect, See Footnote)

Footnotes (1)

1. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities. Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (continued from footnote 3) and (v) 1,224,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth. These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Grossman Adam S

(Last) (First) (Middle)

C/O ADMA BIOLOGICS, INC.

465 STATE ROUTE 17

(Street)

RAMSEY NJ 07446

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/06/2026		F		56,438(1)	D	$15.39	2,148,290	D
Common Stock	03/07/2026		F		29,513(1)	D	$15.39	2,118,777(2)(3)(4)	D
Common Stock								1,143,426	I	See Footnote(5)
Common Stock								580,957	I	See Footnote(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units ("RSUs"). This is not an open market sale of securities.

2. Includes, as of the transaction date, (i) 282,529 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 189,017 unvested RSUs out of 252,022 RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

3. (continued from footnote 2) (iii) 278,864 unvested RSUs out of 557,728 RSUs granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iv) 143,424 unvested RSUs out of 573,695 RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;

4. (continued from footnote 3) and (v) 1,224,943 shares of common stock owned by the Reporting Person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.

5. These shares are owned by Areth, LLC ("Areth"). The Reporting Person is a control person of Areth.

6. These shares are owned by Hariden, LLC ("Hariden"). The Reporting Person is the managing member of Hariden.

	/s/ Adam S. Grossman, by Michael A. Goldstein as Attorney-in-fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ADMA (ADMA) CEO Adam Grossman report?

Adam S. Grossman reported share withholdings for taxes, not open-market trades. A total of 85,951 ADMA common shares were withheld to cover mandatory tax obligations triggered by vesting restricted stock units.

How many ADMA shares were withheld to cover Adam Grossman’s tax obligations?

A combined 85,951 ADMA common shares were withheld at $15.39 per share. These withholdings occurred on March 6 and 7, 2026, and were used solely to satisfy tax requirements tied to vested restricted stock units.

How many ADMA shares does Adam Grossman hold directly after the reported transactions?

Following the tax-withholding events, Adam S. Grossman directly held 2,118,777 shares of ADMA common stock. This figure reflects his remaining direct ownership after the issuer withheld shares to satisfy mandatory tax obligations on vested restricted stock units.

What indirect ADMA shareholdings are associated with Adam Grossman?

Indirectly, 1,143,426 ADMA shares are owned by Areth, LLC and 580,957 shares by Hariden, LLC. Footnotes state Grossman is a control person of Areth and the managing member of Hariden, linking these holdings to him for reporting purposes.

Were Adam Grossman’s recent ADMA share dispositions open-market sales?

No, the dispositions were not open-market sales. Footnotes explain the issuer withheld the 85,951 shares solely to satisfy mandatory tax withholding requirements upon restricted stock unit vesting, rather than selling shares on the open market.

Do the reported ADMA Form 4 transactions involve option exercises or derivative securities?

The reported activity reflects tax-withholding on vested restricted stock units, not option exercises or derivative trades. The derivative position summary is empty, indicating no new option or derivative transactions were recorded in this particular Form 4 filing.